Top
image credit: Vecteezy

Regeneron, AZ team up on drugs for obesity “superpower” gene

July 27, 2021

AZ’s buy into the programme comes a few weeks after Regeneron published findings in the journal Science suggesting that people with certain GPR75 mutations have 54% reduced risk of obesity, based on sequencing data from almost 650,000 people in the US, UK and Mexico.

The study found that individuals who have at least one inactive copy of the GPR75 gene have lower body mass index (BMI) and tend to weigh around 12 pounds less than those without the mutation.

Read More on Pharmaphorum